Temozolomide in the management of dopamine agonist― resistant prolactinomas
- Author
- WHITELAW, B. C1 ; DWORAKOWSKA, D1 8 ; GILBERT, J. A1 ; AYLWIN, S. J. B1 ; THOMAS, N. W2 ; BARAZI, S2 ; RIORDAN-EVA, P3 ; KING, A. P4 ; HAMPTON, T5 ; LANDAU, D. B6 ; LIPSCOMBTT, D7 ; BUCHANAN, C. R1
[1] Department of Endocrinology, King's College Hospital, United Kingdom
[2] Department of Neurosurgery, King's College Hospital, United Kingdom
[3] Department of Ophthalmology, King's College Hospital, United Kingdom
[4] Department of Clinical Neuropathology, King's College Hospital, United Kingdom
[5] Department of Neuroradiology, King's College Hospital, United Kingdom
[6] Department of Clinical Oncology, Guy's Hospital, London, United Kingdom
[7] Department of Endocrinology, Eastbourne District General Hospital, Eastbourne, United Kingdom
[8] Department of Endocrinology and Internal Medicine, Medical University of Gdansk, Gdansk, Poland - Source
Clinical endocrinology (Oxford. Print). 2012, Vol 76, Num 6, pp 877-886, 10 p ; ref : 51 ref
- CODEN
- CLECAP
- ISSN
- 0300-0664
- Scientific domain
- Endocrinology
- Publisher
- Blackwell, Oxford
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Anticancéreux Endocrinologie Prolactinome Résistance Stimulant dopaminergique Traitement Témozolomide Adénome Agent alkylant Endocrinopathie Pathologie de l'hypophyse Tumeur bénigne Tumeur sécrétante
- Keyword (en)
- Antineoplastic agent Endocrinology Prolactinoma Resistance Dopamine agonist Treatment Temozolomide Adenoma Alkylating agent Endocrinopathy Pituitary diseases Benign neoplasm Secretory tumor
- Keyword (es)
- Anticanceroso Endocrinología Prolactinoma Resistencia Estimulante dopaminérgico Tratamiento Temozolomida Adenoma Agente alquilante Endocrinopatía Hipófisis patología Tumor benigno Tumor secretante
- Classification
- Pascal
- 002 Biological and medical sciences / 002A Fundamental and applied biological sciences. Psychology / 002A28 Vertebrates: endocrinology
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B21 Endocrinopathies / 002B21A Hypothalamus. Hypophysis. Epiphysis (diseases) / 002B21A01 Non tumoral diseases. Target tissue resistance. Benign neoplasms
- Discipline
- Endocrinopathies Vertebrates : endocrinology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 25867705
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1111/j.1365-2265.2012.04373.x 
https://dx.doi.org/10.1111/j.1365-2265.2012.04373.x
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2265.2012.04373.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:77:\"Temozolomide in the management of dopamine agonist\u2015 resistant prolactinomas\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Clinical endocrinology (Oxford. Print)\";s:9:\"\u0000*\u0000stitle\";s:31:\"Clin. endocrinol. (Oxf., Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"76\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"877\";s:8:\"\u0000*\u0000epage\";s:3:\"886\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0300-0664\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"WHITELAW\";s:10:\"\u0000*\u0000aufirst\";s:4:\"B. C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:14:\"DWORAKOWSKA, D\";i:1;s:13:\"GILBERT, J. A\";i:2;s:15:\"AYLWIN, S. J. B\";i:3;s:12:\"THOMAS, N. W\";i:4;s:9:\"BARAZI, S\";i:5;s:14:\"RIORDAN-EVA, P\";i:6;s:10:\"KING, A. P\";i:7;s:10:\"HAMPTON, T\";i:8;s:12:\"LANDAU, D. B\";i:9;s:13:\"LIPSCOMBTT, D\";i:10;s:14:\"BUCHANAN, C. R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CLECAP\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:77:\"Temozolomide in the management of dopamine agonist\u2015 resistant prolactinomas\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2265.2012.04373.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:77:\"Temozolomide in the management of dopamine agonist\u2015 resistant prolactinomas\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Clinical endocrinology (Oxford. Print)\";s:9:\"\u0000*\u0000stitle\";s:31:\"Clin. endocrinol. (Oxf., Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"76\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"877\";s:8:\"\u0000*\u0000epage\";s:3:\"886\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0300-0664\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"WHITELAW\";s:10:\"\u0000*\u0000aufirst\";s:4:\"B. C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:14:\"DWORAKOWSKA, D\";i:1;s:13:\"GILBERT, J. A\";i:2;s:15:\"AYLWIN, S. J. B\";i:3;s:12:\"THOMAS, N. W\";i:4;s:9:\"BARAZI, S\";i:5;s:14:\"RIORDAN-EVA, P\";i:6;s:10:\"KING, A. P\";i:7;s:10:\"HAMPTON, T\";i:8;s:12:\"LANDAU, D. B\";i:9;s:13:\"LIPSCOMBTT, D\";i:10;s:14:\"BUCHANAN, C. R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CLECAP\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:77:\"Temozolomide in the management of dopamine agonist\u2015 resistant prolactinomas\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2265.2012.04373.x\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2265.2012.04373.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:77:\"Temozolomide in the management of dopamine agonist\u2015 resistant prolactinomas\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Clinical endocrinology (Oxford. Print)\";s:9:\"\u0000*\u0000stitle\";s:31:\"Clin. endocrinol. (Oxf., Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"76\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"877\";s:8:\"\u0000*\u0000epage\";s:3:\"886\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0300-0664\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"WHITELAW\";s:10:\"\u0000*\u0000aufirst\";s:4:\"B. C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:14:\"DWORAKOWSKA, D\";i:1;s:13:\"GILBERT, J. A\";i:2;s:15:\"AYLWIN, S. J. B\";i:3;s:12:\"THOMAS, N. W\";i:4;s:9:\"BARAZI, S\";i:5;s:14:\"RIORDAN-EVA, P\";i:6;s:10:\"KING, A. P\";i:7;s:10:\"HAMPTON, T\";i:8;s:12:\"LANDAU, D. B\";i:9;s:13:\"LIPSCOMBTT, D\";i:10;s:14:\"BUCHANAN, C. R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CLECAP\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:77:\"Temozolomide in the management of dopamine agonist\u2015 resistant prolactinomas\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2265.2012.04373.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:77:\"Temozolomide in the management of dopamine agonist\u2015 resistant prolactinomas\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Clinical endocrinology (Oxford. Print)\";s:9:\"\u0000*\u0000stitle\";s:31:\"Clin. endocrinol. (Oxf., Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"76\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"877\";s:8:\"\u0000*\u0000epage\";s:3:\"886\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0300-0664\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"WHITELAW\";s:10:\"\u0000*\u0000aufirst\";s:4:\"B. C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:14:\"DWORAKOWSKA, D\";i:1;s:13:\"GILBERT, J. A\";i:2;s:15:\"AYLWIN, S. J. B\";i:3;s:12:\"THOMAS, N. W\";i:4;s:9:\"BARAZI, S\";i:5;s:14:\"RIORDAN-EVA, P\";i:6;s:10:\"KING, A. P\";i:7;s:10:\"HAMPTON, T\";i:8;s:12:\"LANDAU, D. B\";i:9;s:13:\"LIPSCOMBTT, D\";i:10;s:14:\"BUCHANAN, C. R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CLECAP\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:77:\"Temozolomide in the management of dopamine agonist\u2015 resistant prolactinomas\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2265.2012.04373.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:77:\"Temozolomide in the management of dopamine agonist\u2015 resistant prolactinomas\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Clinical endocrinology (Oxford. Print)\";s:9:\"\u0000*\u0000stitle\";s:31:\"Clin. endocrinol. (Oxf., Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"76\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"877\";s:8:\"\u0000*\u0000epage\";s:3:\"886\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0300-0664\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"WHITELAW\";s:10:\"\u0000*\u0000aufirst\";s:4:\"B. C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:14:\"DWORAKOWSKA, D\";i:1;s:13:\"GILBERT, J. A\";i:2;s:15:\"AYLWIN, S. J. B\";i:3;s:12:\"THOMAS, N. W\";i:4;s:9:\"BARAZI, S\";i:5;s:14:\"RIORDAN-EVA, P\";i:6;s:10:\"KING, A. P\";i:7;s:10:\"HAMPTON, T\";i:8;s:12:\"LANDAU, D. B\";i:9;s:13:\"LIPSCOMBTT, D\";i:10;s:14:\"BUCHANAN, C. R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CLECAP\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:77:\"Temozolomide in the management of dopamine agonist\u2015 resistant prolactinomas\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
